Valencia

• First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer Ended
  2023-504012-16-00 7 2024-04-29 Unresectable Locally Advanced or Metastatic Cancer
• A clinical research study to learn if baxdrostat works at reducing ambulatory blood pressure and is safe for people with high blood pressure … Ended
  2023-507640-36-00 5 2024-04-29 Resistant hypertension (rHTN) defined as blood pressure that remains h
• MYK-224 in Heart Failure with Preserved Ejection Fraction (HFpEF) Ended
  2023-505919-21-00 4 2024-04-25 Heart failure with preserved ejection fraction (HFpEF)
• Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended
  2022-502899-23-00 5 2024-04-23 Hepatic Encephalopathy (OHE)
• Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer Ended
  2023-504630-22-00 7 2024-04-19 Non-Small Cell Lung Cancer
• A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended
  2023-505857-42-00 4 2024-04-19 Chronic Kidney Disease, Type 2 diabetes
• MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended
  2023-506425-12-00 5 2024-04-17 Uncontrolled and Resistant Hypertension
• A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED) Ended
  2023-507217-10-00 5 2024-04-12 Thyroid eye disease
• A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended
  2023-503693-20-01 5 2024-04-10 Severe eosinophilic asthma
• A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet … Ended
  2023-505414-15-00 4 2024-04-10 Dermatitis, Atopic
• PH2a, VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living with HIV-1 Ended
  2023-507173-18-00 4 2024-04-09 HIV Infections
• FIH study of ALE.C04 anti-CLDN1 mAb monotherapy or in combination with pembrolizumab in patients with R/M HNSCC Ended
  2023-505145-93-00 7 2024-03-21 Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma
• A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors Ended
  2023-504824-24-00 3 2024-03-15 Arm A: Diagnosed with uterine serous carcinoma (USC) Arm B: Diagnosed
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 4 2024-03-13 Heart Failure
• A clinical study of MK-6194 for the treatment of Systemic Lupus Erythematosus (SLE) (MK-6194-006) Ended
  2023-505520-61-00 10 2024-03-11 Systemic Lupus Erythematosus
• A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 … Ended
  2023-506092-10-00 4 2024-03-11 Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous
• Study Drug vs Placebo as an “add on” treatment for Severe Community-Acquired Pneumonia. Ended
  2023-505985-28-01 4 2024-03-04 Severe Community-Acquired Pneumonia
• A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended
  2023-505396-71-00 4 2024-03-01 Early Alzheimer’s Disease with Biomarkers of Inflammation
• GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Ended
  2022-502453-33-00 4 2024-02-26 Advanced Endometrial Cancer
• This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu … Ended
  2023-504800-28-00 3 2024-02-23 Chronic Inducible Urticaria
• This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu … Ended
  2023-504799-94-00 4 2024-02-20 Chronic Spontaneous Urticaria
• A first-in-human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or M … Ended
  2023-507321-42-00 1 2024-02-15 Myelodysplastic syndrome (MDS)
• Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended
  2023-507358-34-00 4 2024-02-13 For the treatment of patients with chronic non-specific low back pain
• THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICA … Ended
  2023-507304-32-00 6 2024-02-09 Chronic Obstructive Pulmonary Disease

Showing 1,489–1,512 of 1,853 trials